Short answer
AVITA Medical, Inc. (RCEL) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
AVITA Medical, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 with detailed financial results
- Market focus: AVITA Medical’s quarterly performance and financial condition update
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue reached a record $21.7M, up 18% year over year and 13% sequentially, led by RECELL at $18.5M
- Gross margin expanded to 81.9% from 81.2%, while operating expenses fell 6% to $24.6M
- 2026 revenue guidance increased to $86M-$89M from $80M-$85M, implying 20%-24% growth versus $71.6M in 2025
- Net cash use improved to approximately $3.2M, with $11.1M liquidity and expected cash-flow breakeven in Q4 2026
- Proposed 2027 CMS reimbursement changes could establish national RECELL physician payment and increase facility rates, supporting adoption if finalized
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AVITA Medical, Inc. 8-K filings
Get the next RCEL 8-K as it lands
Follow RCEL for push alerts, or ask the research agent what this filing means.